{
    "clinical_study": {
        "@rank": "5080", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give zintevir (AR177) to\n      asymptomatic (no symptoms) HIV-infected patients.\n\n      Zintevir belongs to a new class of anti-HIV drugs, the integrase inhibitors. HIV uses the\n      protein integrase to infect a cell. Integrase inhibitors block integrase and may stop\n      replication of HIV."
        }, 
        "brief_title": "Safety and Effectiveness of Zintevir (AR177) Given to HIV-Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Zintevir belongs to a new class of anti-HIV drugs, the integrase inhibitors. The HIV-1 virus\n      uses the protein integrase to incorporate its genetic material into the infected host cell.\n      Integrase inhibitors block integrase and may stop replication of the HIV-1 virus.\n\n      In this open-label, Phase I/II study, 3 groups of HIV-positive patients (12 patients total)\n      receive escalating doses of intravenous zintevir for 14 consecutive days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        You may be eligible for this study if you:\n\n          -  Are HIV-positive, but do not have any symptoms of HIV infection.\n\n          -  Have a CD4 count greater than 200 cells/mm3.\n\n          -  Have a viral load (level of HIV in the body) greater than 4,000 copies/ml.\n\n          -  Are at least 18 years old.\n\n        Exclusion Criteria\n\n        You will not be eligible for this study if you:\n\n          -  Tend to have abnormal bleeding or other blood problems.\n\n          -  Have an active AIDS-defining illness.\n\n          -  Have a history of serious disease or illness.\n\n          -  Abuse alcohol or drugs.\n\n          -  Have received certain medications."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "12", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002403", 
            "org_study_id": "290A", 
            "secondary_id": [
                "UNAP 3", 
                "AR177-003"
            ]
        }, 
        "intervention": {
            "intervention_name": "Zintevir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "HIV Integrase Inhibitors", 
                "Integrase Inhibitors"
            ]
        }, 
        "keyword": [
            "HIV-1", 
            "Dose-Response Relationship, Drug", 
            "HIV Integrase Inhibitors", 
            "HIV Integrase"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Cornell AIDS Clinical Trials Unit"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I/II Multiple Dose Study to Evaluate the Safety, Pharmacokinetic Profile and Virologic/Immunologic Activity of Zintevir (AR177) in HIV-1 Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002403"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aronex Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1999"
    }, 
    "geocoordinates": {
        "Cornell AIDS Clinical Trials Unit": "40.714 -74.006"
    }
}